Switzerland’s Lonza , the world’s largest contract drug manufacturer, raised the full-year target for its core profit margin to between 33% and 34% on Wednesday, citing strong operational execution and contributions from maturing growth projects.
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
